Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus

Cancer

Volumn 86, Issue 5, 1999, Pages 756-763

  Hanas, Jay S ^a   Lerner, Megan R ^a,b   Lightfoot, Stan A ^a   Raczkowski, Carl ^a   Kastens, Donald J ^a   Brackett, Daniel J ^a,b   Postier, Russell G ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Barrett esophagus; Cell cycle regulation; Dysplasia; Esophageal adenocarcinoma; Immunohistochemistry; p21; p53; Tumor progression; Tumor suppressors

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DYSPLASIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ADENOCARCINOMA; ADULT; AGED; BARRETT ESOPHAGUS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PRECANCEROUS CONDITIONS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033198150     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990901)86:5<756::AID-CNCR9>3.0.CO;2-X     Document Type: Article

References (31)

1. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1986;315:362-71.
2. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994;25:982-93.
3. Winters C, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF, et al. Barrett's esophagus: a prevalent occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
4. Silverberg E, Boring CC, Squires TS. Cancer statistics. CA Cancer J Clin 1990;40:9-27.
5. Haggitt RC Adenocarcinoma in Barrett's esophagus: a new epidemic? Hum Pathol 1992;23:475-6.
6. Pera M, Cameron AJ, Trastek VF, Carpender HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104:510-3.
7. Hameeteman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
8. Haggitt RC, Tryzelaar J, Ellis FH, Colcher H. Adenocarcinoma complicating columnar epithelial lined (Barrett's) esophagus. Am J Clin Pathol 1978;70:1-5.
9. McArdle JE, Lewin KJ, Randall G, Weinstein W. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum Pathol 1992;23:479-82.
10. Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS. Flow cytometry complements histology in detecting patients at risk for Barrett's adenocarcinoma. Gastroenterology 1987;93:1-11.
11. Reid BJ, Sanchez CA, Blount PL, Levine DS. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993;105:119-29.
12. 1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
13. Ramel S, Reid BJ, Sanchez CA, Blount PL, Levine DS, Neshat K. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 1992;102:1220-8.
14. Wang D-Y, Xiang Y-Y, Tanaka M, Li X-R, Li J-L, Shen Q. High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer 1994;74:3089-95.
15. Harris CC, Hollstein M Clinical implications of the p53 tumor suppresser gene. N Engl J Med 1993;329:1318-27.
16. Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-95.
17. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 1993;75:805-16.
18. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
19. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-5.
20. Cip1 in muscle and other terminally differentiating cells. Science 1995;267:1024-7.
21. WAF1. Cancer Res 1995;55:4536-9.
22. WAF/CIP1/SDI1 gene products in Barrett's esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol 1996;27: 1211-20.
23. Remmele W, Schicketanz K-H. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer: computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 1993;189:862-6.
24. Backe J, Gassel AM, Hauber K, Krebs S, Bartek J, Caffier H, et al. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int J Gynecol Pathol 1997;16:361-8.
25. Waf1/Cip1 expression in normal human tissues. Am J Pathol 1996;148:825-35.
26. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995;55: 2910-9.
27. WAF1/CIP1 in normal, hyperplastic, and neoplastic uterine tissues. Hum Pathol 1997;28: 60-5.
28. WAF1/CIP1 in human brain tumors. Oncogene 1995;11:2021-8.
29. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995; 147:884-8.
30. WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer 1995;63:611-5.
31. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Tekevchi S, Yang R, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994;84:3781-4.